Akebia Therapeutics, Inc. (AKBA) Guidance & Earnings Results
On 2026-02-26 Akebia Therapeutics, Inc. raised guidance: "Expect significant Vafseo revenue growth in…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AKBAAkebia Therapeutics, Inc.Follow AKBA — free
—
Price chart with a free account
- Market cap
- 157.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 26 Feb 26 | Raised | Expect significant Vafseo revenue growth in 2026 |
| 12 Jan 26 | Raised | Expects revenue growth to resume in Q1 2026; underlying demand $10.5-11.5M in Q4 2025 |
Akebia Therapeutics, Inc. — questions
- What guidance did Akebia Therapeutics, Inc. give?
- On 2026-02-26: "Expect significant Vafseo revenue growth in 2026"
- When does Akebia Therapeutics, Inc. report earnings?
- Akebia Therapeutics, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Akebia Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.